Management of Hemorrhage Related to Direct Action Oral Anticoagulant Medication
Journal of Cardiac Arrhythmias · 2019
DOI: 10.24207/jca.v32i2.008_in ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiac Arrhythmias, 2019. Verfasst von Isabela Ramos Ali Ganem und 2 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Direct Oral Anticoagulant – DOACs) are a new class of anticoagulant that directly inhibit the trombine (dabigatran) or Xa factor (rivaroxabane , edoxabane and apixabane) in the coagulation cascade. These medications are being more frequently used for the treatment and prevention of thrombolytic events, mainly in patients with atrial fibrillation, in substitute to varfrine or other vitamin K antagonists (VKAs). Although the incidence of hemorrhage is higher in AVKs than in DOACs, these events may also occur in this group, even in the form of intracranial hemorrhage (ICH), with risk of death. Nowadays, DOACs indications have progressively enhanced and the availability of their specific reverse agents certainly will enhance the safety of their usage. Idarucizumab, reverse agent of dabigatrane, and alpha andexanet, reverse agent of Xa factor, have been approved by the Food and Drug Administration in the United States and ciraparantag may be approved in a near future.
Objective
To review the literature on the manage of hemorrhage related to the use of DOACs.
Methods
Review of literature that used articles from 1998 to 2017, from several platforms and journals.
Conclusion
DOACs constitute a great advance in prophylaxis and treatment of thrombolytic diseases, which presents elevated morbidymortality, and hemorrhages are the main adverse events related to their usage, being rarely necessary the immediate reverse of the anticoagulation. However, the existence of DOACs specific reverse agents enhance the safety of patients, whose anticoagulation may be rapidly reversed if necessary.
Zitieren
APA
Ganem, I. R. A., Martins, L. C. B., & Tomé, C. E. M. (2019). Management of Hemorrhage Related to Direct Action Oral Anticoagulant Medication. Journal of Cardiac Arrhythmias. https://doi.org/10.24207/jca.v32i2.008_in
Vancouver
Ganem IRA, Martins LCB, Tomé CEM. Management of Hemorrhage Related to Direct Action Oral Anticoagulant Medication. Journal of Cardiac Arrhythmias. 2019. doi:10.24207/jca.v32i2.008_in
BibTeX
@article{Ganem2019,
author = {Ganem, Isabela Ramos Ali and Martins, Luiz Claudio Behrmann and Tomé, Carlos Eduardo Mendonça},
title = {Management of Hemorrhage Related to Direct Action Oral Anticoagulant Medication},
journal = {Journal of Cardiac Arrhythmias},
year = {2019},
doi = {10.24207/jca.v32i2.008_in}
}
EUVIMED